According to the British Heart Foundation (2024), an estimated 56 million women and 45 million men worldwide were stroke survivors, reflecting the immense global burden of cerebrovascular disease. The same source also reported that, as of 2022, nearly 250 million people globally were living with coronary heart disease, further emphasizing the need for effective interventional solutions.
In 2024, the global market was valued at USD 1,656.88 million and is projected to reach USD 2,806.85 million by 2032, driven by a surge in the prevalence of neurological and cardiovascular disorders such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis — all of which require rapid and effective medical intervention.
The market is also benefiting from a rising preference for minimally invasive procedures, which offer reduced complication rates and faster recovery compared to conventional surgeries. Additionally, technological innovations and product advancements — including the launch of next-generation thrombectomy systems designed to enhance procedural precision and patient outcomes — are further accelerating market growth.
Collectively, these developments are creating strong momentum for the thrombectomy devices market, supporting consistent expansion over the forecast period.
DelveInsight’s Thrombectomy Devices Market Insights report provides comprehensive analyses of current and forecast market trends, leading company shares, growth drivers, challenges, and emerging opportunities within the thrombectomy devices landscape.
Request for a sample page report @ https://www.delveinsight.com/report-store/thrombectomy-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Thrombectomy Devices Market Report
* The Thrombectomy Devices market is expected to experience steady growth at a moderate CAGR between 2025 and 2032. According to DelveInsight, North America is projected to lead the global market throughout the forecast period, supported by strong healthcare infrastructure, high disease prevalence, and early adoption of advanced medical technologies.
* Key companies operating in the Thrombectomy Devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Innova Vascular, Vesalio Inc., and ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., among others.
* In February 2025, Stryker completed its acquisition of Inari Medical, Inc., strengthening its thrombectomy portfolio with the FlowTriever® System for pulmonary embolism and ClotTriever® System for peripheral vessel thrombectomy — creating strong synergies within its Neurovascular division.
* That same month, Shanghai Tendfo Medical Device Co., Ltd. received NMPA approval in China for its Tendvia™ Pulmonary Artery Thrombectomy System, a minimally invasive transcatheter device for the removal of clots in patients with acute high-risk or intermediate-risk pulmonary embolism.
* In September 2024, Argon Medical Devices launched the CLEANER Vac™ Thrombectomy System, a large-bore aspiration device designed to efficiently remove thrombus from the peripheral venous system and enhance blood flow in affected vessels.
* Earlier, in January 2023, phenox Inc. obtained FDA 510(k) clearance for its pRESET® Thrombectomy Device, specifically intended for treating acute ischemic stroke by restoring cerebral blood flow in patients with arterial occlusions.
* The Thrombectomy Devices market is expected to expand at a steady CAGR from 2025 to 2032. According to DelveInsight, North America will likely remain the leading region throughout the forecast period, driven by a high incidence of cardiovascular and neurological disorders, advanced healthcare systems, and widespread use of innovative medical technologies.
* Major players in the Thrombectomy Devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Innova Vascular, Vesalio Inc., and ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., among others.
* In February 2025, Stryker completed its acquisition of Inari Medical, Inc., enhancing its thrombectomy portfolio with the FlowTriever® System for pulmonary embolism and the ClotTriever® System for peripheral thrombectomy, strengthening synergies within its neurovascular business.
* Also in February 2025, Shanghai Tendfo Medical Device Co., Ltd. received NMPA approval in China for the Tendvia™ Pulmonary Artery Thrombectomy System, a minimally invasive transcatheter solution for patients with acute pulmonary embolism.
* In September 2024, Argon Medical Devices introduced the CLEANER Vac™ Thrombectomy System, a disposable, large-bore aspiration device designed to quickly and efficiently remove thrombus from the peripheral venous system.
* Earlier, in January 2023, phenox Inc. gained FDA 510(k) clearance for its pRESET® Thrombectomy Device, engineered for treating acute ischemic stroke by restoring cerebral blood flow in patients with blocked arteries.
To read more about the latest highlights related to the Thrombectomy Devices market, get a snapshot of the key highlights entailed in the Global Thrombectomy Devices Market Report
Thrombectomy Devices Overview
Thrombectomy devices are specialized medical tools used to remove blood clots from blood vessels, helping restore proper blood flow and prevent serious complications such as stroke, pulmonary embolism, and peripheral artery disease. These devices are essential in neurovascular, cardiovascular, and peripheral vascular procedures, where they play a crucial role in treating life-threatening thromboembolic conditions.
The thrombectomy devices market is witnessing robust growth, driven by the increasing global prevalence of stroke, coronary heart disease, pulmonary embolism, and deep vein thrombosis (DVT). The growing aging population, which faces a higher risk of vascular disorders, along with the rising preference for minimally invasive treatment techniques, is further accelerating market demand.
Ongoing technological innovations and new product introductions by major industry players are significantly contributing to market expansion. The latest thrombectomy systems are engineered to enhance procedural precision, patient safety, and clinical outcomes, while reducing recovery times and overall healthcare costs.
Geographically, North America leads the global market, supported by an advanced healthcare system, strong presence of key manufacturers, and favorable reimbursement policies. Meanwhile, Asia-Pacific and Europe are rapidly emerging as high-growth regions due to a rising disease burden, growing awareness of thromboembolic conditions, and broader access to advanced medical technologies.
Overall, thrombectomy devices are expected to remain a cornerstone of vascular intervention therapies, with the global market poised for steady and sustained growth in the years ahead.
Thrombectomy Devices Market Insights
North America is expected to lead the thrombectomy devices market in 2024, driven by several key factors. The region’s dominance is primarily attributed to the high incidence of neurovascular, peripheral, and coronary vascular disorders, a rapidly aging population, and a continuous wave of technological advancements and product innovations from major device manufacturers. In addition, the presence of well-established healthcare infrastructure, supportive reimbursement policies, and growing awareness of minimally invasive treatment options are anticipated to further solidify North America’s leading position throughout the forecast period.
According to the Centers for Disease Control and Prevention (CDC, 2024), over 795,000 Americans experience a stroke each year, with nearly 185,000 (one in four) occurring in individuals with a previous stroke. Furthermore, approximately 900,000 people in the U.S. are affected by venous thromboembolism (VTE) annually, highlighting the growing clinical need for effective clot-removal technologies such as thrombectomy devices.
The rising prevalence of coronary heart disease (CHD) and peripheral artery disease (PAD) further supports this upward trend. CDC data (June 2024) indicated that about 20.5 million Americans were living with CHD in 2022, while nearly 6.5 million adults aged 40 and above were diagnosed with PAD. These statistics emphasize the increasing demand for thrombectomy systems, which play a critical role in eliminating blood clots, restoring vascular patency, and preventing serious complications across a range of cardiovascular and peripheral conditions.
To know more about why North America is leading the market growth in the Thrombectomy Devices market, get a snapshot of the Thrombectomy Devices Market Outlook
Thrombectomy Devices Market Dynamics
According to the British Heart Foundation (2024), approximately 56 million women and 45 million men globally are stroke survivors, underscoring the immense worldwide burden of cerebrovascular disease. The foundation also reported that nearly 250 million people were living with coronary heart disease as of 2022, highlighting the critical need for effective interventional therapies. Similarly, the World Stroke Organization (2023) noted that 1 in 4 adults over 25 is likely to experience a stroke during their lifetime, with over 110 million individuals already affected worldwide. In such scenarios, thrombectomy devices play a vital role by mechanically removing clots that obstruct arteries or veins, helping to restore normal blood flow in acute, life-threatening conditions such as ischemic stroke and peripheral arterial thrombosis.
In Australia, data from the National Institute of Health (2022) revealed that more than 17,000 individuals develop venous thromboembolism (VTE) each year, reinforcing the growing demand for advanced interventional solutions like thrombectomy systems.
Furthermore, the British Heart Foundation (2025) reported that over 7.6 million people in the UK were living with heart and circulatory diseases in 2024 — comprising 4 million men and 3.6 million women. This number is projected to increase by 1 million by 2030 and 2 million by 2040, illustrating the expanding dependence on innovative medical technologies such as thrombectomy devices to effectively remove clots and restore vascular circulation.
Additionally, the American Heart Association (2023) estimated that more than 12 million Americans and nearly 200 million people globally are living with peripheral artery disease (PAD). The growing prevalence of PAD continues to drive the demand for thrombectomy devices, which are extensively used to clear arterial blockages outside the heart and brain — improving blood flow, alleviating symptoms, and enhancing long-term patient outcomes.
Thrombectomy Devices Market Drivers:
* Growing prevalence of neurological and cardiovascular diseases
* Increasing product development activities among the key market players
Get a sneak peek at the Thrombectomy Devices market dynamics
Scope of the Thrombectomy Devices Market Report:
* Coverage: Global
* Study Period: 2022 to 2032
* Key Thrombectomy Devices Companies: Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Innova Vascular, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.
Which MedTech key players in the Thrombectomy Devices market are set to emerge as the trendsetter, explore @ Thrombectomy Devices Companies
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Thrombectomy Devices Market is anticipated to grow at a CAGR of 6.83% through 2032, according to DelveInsight
